Skip to content
Articles
Close Articles
Open Articles
Latest Articles
JCAD Archives
Acne & Rosacea
Aesthetic Dermatology
Cutaneous Oncology
Dermatologic Surgery
Device-Based Therapies
Eczema
Hair and Nails
Hidradenitis Suppurativa
Infectious Disease
Psoriasis
Pigmentation Disorders
Practice Management
Skin of Color
NP+PA Archives
JCAD.TV
Close JCAD.TV
Open JCAD.TV
Meeting Coverage
Maui Derm NP+PA Fall Coverage 2025
AAD Innovation Academy 2025
AAD Meeting Coverage 2025
Expert Perspectives
Acne
Alopecia Areata
Atopic Dermatitis
Chronic Hand Eczema
Generalized Pustular Psoriasis
Insights in Pediatric Dermatitis
Melanoma
Prurigo Nodularis
Psoriasis
Skincare Science
Skincare Science: Sensitive Skin
Vitiligo
Journal Review
Case Series
Original Research Videos
Video Case Reports
Podcasts & Audio
Full Index
Patient Cases
Atopic Dermatitis
Psoriasis
Dialogues and Reviews
Journal Highlights and Issue Discussions
NP+PA
About
Close About
Open About
About JCAD
Author Guidelines
Permissions
Advertise
About JCAD
Author Guidelines
Permissions
Advertise
Contact Us
Subscribe
James Song, MD: Live from Elevate-Derm West—Why Older Immunosuppressant Agents are Still Relevant in 2024
Dialogues and Reviews
Dr. Song provides helpful clinical tips for treating patients with methotrexate.
More episodes:
JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea
Listen to episode
Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis
Listen to episode
JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events
Listen to episode
James Del Rosso, DO: Dermatology Year in Review 2024
Listen to episode
JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea
Listen to episode
James Song, MD: Live from Elevate-Derm West—New Topical and Systemic Agents for Atopic Dermatitis
Listen to episode
James Del Rosso, DO: New and Exciting Indications for Bimekizumab, Nemolizumab, and Lebrikizumab
Listen to episode
